How This Evidence Evolved
PD-L1 Testing and Standardization
From discovery of a biomarker to the challenge of multiple assays and scoring systems
Timeline
Early observations and pilot data that first suggested a new direction
Landmark RCTs and pivotal trials that established the evidence base
Concordance of PD-L1 scoring across four assays
Inter-assay concordance and interobserver agreement
Follow-up studies, subgroup analyses, and real-world validation
Progression-free survival in PD-L1 CPS>=10 subgroup
PFS and OS (KEYNOTE-811 interim).
Complete pathologist agreement in 543 urothelial cases: 82.1% before versus 93.9% after AI-guided reassessment.
Current standard of care and ongoing research directions
Landmark Trials in This Story
Pembrolizumab for the treatment of non-small-cell lung cancer.
Validation ORR, PD-L1 ≥50%: 45.2%.
PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project
Concordance of PD-L1 scoring across four assays
PD-L1 Immunohistochemistry Comparability Study in Real-Life Clinical Samples: Results of Blueprint Phase 2 Project
Inter-assay concordance and interobserver agreement
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial
Progression-free survival in PD-L1 CPS>=10 subgroup
Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial.
PFS and OS (KEYNOTE-811 interim).
An artificial intelligence-powered PD-L1 combined positive score (CPS) analyser in urothelial carcinoma alleviating interobserver and intersite variability.
Complete pathologist agreement in 543 urothelial cases: 82.1% before versus 93.9% after AI-guided reassessment.
Explore the evidence yourself
Ask AttendMe about any trial, guideline, or clinical question. Evidence-ranked answers from 3.7M+ peer-reviewed articles.